2024-10-11 - Analysis Report
## Vertex Pharmaceuticals Inc (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening diseases.

**Performance Analysis:**

**1. Performance Comparison:**

* VRTX's cumulative return is **171.79%**, significantly higher than the S&P 500 (VOO) cumulative return of **134.82%**.
* The outperformance of VRTX compared to the S&P 500 is **30.12%**.
* This outperformance places VRTX in the **68.13%** percentile compared to its historical performance, indicating a relatively strong performance relative to its past behavior.

**2. Recent Price Action:**

* Closing Price: **467.97**
* 5-Day Moving Average: **456.87**
* 20-Day Moving Average: **467.42**
* 60-Day Moving Average: **477.57**

The stock price is currently trading slightly below its 20-day moving average, indicating a short-term downward trend. The 60-day moving average suggests a more significant downtrend in the longer term.

**3. Technical Indicators:**

* **RSI (Relative Strength Index): 43.14** - This suggests that VRTX is currently in a neutral territory, not oversold or overbought. 
* **PPO (Percentage Price Oscillator): -0.03** - This indicates a slight downward momentum, confirming the short-term bearish trend observed in the moving averages. 
* **Delta_Previous_Relative_Divergence: -13.46** - This negative value suggests a recent short-term downward trend in the stock's relative performance.
* **Expected_Return: 11.56%** - This indicates a potential for a 11.56% return over the next 5 years, exceeding the expected return from the S&P 500. This, however, is a projected value and is subject to market volatility.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

The most recent earnings report (2024-08-02) shows a significant decrease in EPS, which might have caused the recent downward trend in the stock price. It's crucial to analyze the factors contributing to this dip and the company's future outlook to understand its long-term impact.  

**5. News and Recent Issues:**

**Recent Market Outlook:**

* **FINBOLD** reported that VRTX's stock price has been declining recently due to disappointing Q2 earnings, which were below analyst expectations. 

**Analyst Opinions:**

* **MarketBeat** reports that VRTX has a "Moderate Buy" rating from analysts, with an average price target of $500. 

**Performance Highlights:**

* VRTX has demonstrated impressive growth over the past years, with its portfolio of cystic fibrosis therapies contributing significantly to its success.

**6. Overall Analysis:**

VRTX has outperformed the market over the long term, but recent earnings results have impacted the stock price negatively. While the long-term outlook remains promising, the recent downward trend suggests potential short-term volatility. Investors should monitor the company's upcoming earnings reports and any further news regarding its cystic fibrosis therapies to make informed investment decisions.  

**7. Key Takeaways:**

* VRTX has historically outperformed the S&P 500, but recent earnings have resulted in a short-term downward trend.
* Technical indicators signal a potential for further downward movement in the short term, but the long-term outlook remains optimistic.
* Analyst sentiment is positive, with a "Moderate Buy" rating and an average price target of $500.
* Future performance will largely depend on the company's continued success in the cystic fibrosis market and its ability to navigate the challenges of the recent earnings dip. 
